In addition, the District Court found that Teva's use of the analytical methods claimed in the '866 patent fell within the safe harbor provisions of 35 U.S.C § 271(e)(1). The situation was different with regard to Momenta's infringement allegations against Amphastar, inter alia, because Amphastar manufactured enoxaparin in the U.S. In this case, the District Court held that Amphastar's activities fell within the safe harbor provisions of the Hatch-Waxman Act. The Federal Circuit affirmed the District Court's decision as to Teva (relating to infringement under § 271(g) but vacated the lower court's grant of summary judgment in Amphastar's favor, in an opinion by Judge Wallach joined by Judge Moore and in part by Judge Dyk, who also dissented in part. The portion of the decision related to (non)infringement under § 271(g) was straightforward: the '866 patent claims did not encompass methods of "making" the enoxaparin.